



(12) Translation of
European patent specification

(11) NO/EP 3976012 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/135 (2006.01)

A61P 25/00 (2006.01)

A61K 9/00 (2006.01)

A61P 43/00 (2006.01)

A61K 9/08 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.04.15
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.03.20
(86)	European Application Nr.	20754342.2
(86)	European Filing Date	2020.05.29
(87)	The European Application's Publication Date	2022.04.06
(30)	Priority	2019.05.31, US, 201962855543 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Afyx Therapeutics A/S, Ole Maaløes Vej 3, 2200 Copenhagen N, Denmark
(72)	Inventor	HOLM, Per, Grøndals Parkvej 12, 2720 Vanløse, Denmark PEDERSEN, Ole, Liljehaven 73, 2765 Smørum, Denmark KRUSZ, John, Claude, 5446 Glen Lakes Drive, Dallas, TX 75231-4308, USA
(74)	Agent or Attorney	Nordic Patent Service A/S, Bredgade 30, 1260 KØBENHAVN K, Denmark

(54) Title **INTRANASAL ADMINISTRATION OF KETAMINE TO CLUSTER HEADACHE PATIENTS**

(56) References

Cited:

US-A1- 2018 177 744, US-A1- 2014 275 278
John Claude Krusz: "Intranasal Ketamine for the Relief of Cluster Headache", Practical Pain Management Journal, 21 June 2019 (2019-06-21), pages 1-8, XP055739733, Retrieved from the Internet: URL:<https://www.practicalpainmanagement.com/pain/headache/intranasal-ketamine-relief-cluster-headache> [retrieved on 2020-10-14]
Ruppen ET AL: "The analgesic effect of combined treatment with intranasal S-ketamine and intranasal midazolam compared with morphine patient-controlled analgesia in spinal surgery patients: a pilot study", Journal of Pain Research, 13 February 2015 (2015-02-13), page 87, XP093020497, DOI: 10.2147/JPR.S75928 Retrieved from the Internet: URL:<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334346/pdf/jpr-8-087.pdf>
Carr Daniel B ET AL: "Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study", PAIN, vol. 108, no. 1, 1 March 2004 (2004-03-01) , pages 17-27, XP055944962, NL ISSN: 0304-3959, DOI: 10.1016/j.pain.2003.07.001
STUART M. PEARSON ET AL: "Effectiveness of Oxygen and Other Acute Treatments for Cluster Headache: Results From the Cluster Headache Questionnaire, an International Survey", HEADACHE., vol. 59, no. 2, 11 January 2019 (2019-01-11), pages 235-249, XP055739828, United States ISSN: 0017-8748, DOI: 10.1111/head.13473
GRANATA L ET AL: "Ketamine i. v. for the treatment of cluster headaches", SCHMERZ, DER, SPRINGER VERLAG, BERLIN, DE, vol. 30, no. 3, 11 April 2016 (2016-04-11) , pages 286-288, XP035884049, ISSN: 0932-433X, DOI: 10.1007/S00482-016-0111-Z [retrieved on 2016-04-11]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Vandig sammensetning for anvendelse ved behandling av klyngehodepine, hvori den vandige sammensetningen omfatter ketamin i et område på fra 50 mg/ml til 200 mg/ml basert
5 på det totale volumet av sammensetningen, og behandlingen omfatter intranasal administrering av den vandige sammensetningen i form av en nesenspray.
2. Sammensetningen for anvendelse ifølge krav 1, hvori klyngehodepinen er i form av kronisk klyngehodepine eller i form av episodisk klyngehodepine.
10
3. Sammensetningen for anvendelse ifølge krav 1, hvori den vandige sammensetningen administreres intranasalt med en nesenspray i én eller flere enhetsdoser.
4. Sammensetningen for anvendelse ifølge krav 1, hvori nesensprayanordningen omfatter
15 én eller flere enhetsdoser av ketamin.